Invivyd Inc Ordinary Shares IVVD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.61
- Day Range
- $0.61–0.68
- 52-Week Range
- $0.53–3.07
- Bid/Ask
- $0.67 / $0.69
- Shares Outstanding
- 294.76M
- Market Cap
- $197.13M
- Volume/Avg
- 3M / 5M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.99
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 122
- Website
- https://www.invivyd.com
Valuation
|
Metric
|
IVVD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.05 |
Price/Sales | 2.99 |
Price/Cash Flow | — |
Price/Earnings
IVVD
Financial Strength
|
Metric
|
IVVD
|
|---|---|
Quick Ratio | 5.54 |
Current Ratio | 5.87 |
Interest Coverage | — |
Quick Ratio
IVVD
Profitability
|
Metric
|
IVVD
|
|---|---|
Return on Assets (Normalized) | −49.75% |
Return on Equity (Normalized) | −63.10% |
Return on Invested Capital (Normalized) | −61.08% |
Return on Assets
IVVD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|RVd!Lq | LOCK|Ybrm | $126B | |||
| Moderna Inc
MRNA
| LOCK|Tv$vnR< | LOCK|<f | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|f^>!#Z | LOCK|gp>?J | $80B | |||
| argenx SE ADR
ARGX
| LOCK|n^$%H>w | LOCK|#p< | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|jl#F&l | LOCK|$? | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%d%%qc | LOCK|GpF&r | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|QLq!b&C | LOCK|^FSqM | $26B | |||
| Incyte Corp
INCY
| LOCK|BzNb^@! | LOCK|<< | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|>%@wRJ | LOCK|Tdy | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|b>>Y@< | LOCK|$? | $14B |
United States